Ocugen Inc. (NASDAQ: OCGN) released its first‑quarter 2026 financial results, reporting a net loss of $19.2 million, or $0.06 per share, versus an analyst estimate of a $0.05 loss. Revenue reached $1.53 million, beating the consensus estimate of $1.2 million and marking a 10% increase from the $1.38 million reported in Q1 2025.
The company completed a private offering of $115 million in convertible senior notes due 2034, with $112.1 million expected to close on May 7 2026. Approximately $32.7 million of the proceeds will be used to repay the Avenue Capital loan, leaving the company with a cash balance that extends its runway to 2028.
Enrollment for the Phase 3 OCU400 liMeliGhT trial and the Phase 2/3 GARDian3 trial for OCU410ST finished ahead of schedule. Ocugen plans to file a rolling BLA for OCU400 in Q3 2026 and aims to submit the final BLA by Q2 2027, while the OCU410ST BLA is targeted for mid‑2027.
Operating expenses rose to $19.4 million, driven by R&D spending of $11.3 million and G&A costs of $8.1 million, up from $9.5 million and $6.5 million respectively in Q1 2025. The increase reflects intensified investment in clinical development and expanded support functions.
Management highlighted that the company is executing well against its plans, citing high productivity per employee, a solid cash position, and milestone achievements. Investors reacted negatively, focusing on the EPS miss and higher operating costs, despite the revenue beat and extended runway.
The results underscore Ocugen’s continued focus on advancing its gene‑therapy pipeline while managing cash resources. The extended runway provides a buffer to reach regulatory milestones, but the persistent losses and rising expenses signal that profitability remains a long‑term goal.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.